VALFIX Medical Announces Allowance of Three New Patents, Bringing Total IP Portfolio to 12

DOVER, Del. - Aug. 6, 2025 - PRLog -- VALFIX Medical Inc., a robotic transcatheter solutions company, pioneering a less invasive approach to mitral valve repair, today announced the allowance of three new patents in the United States, Israel and the European Union. These new patents, which focus on the company's proprietary anchoring and locking technologies, bring VALFIX Medical's total intellectual property portfolio to 12 granted patents, with many more pending globally.

The newly granted patents cover key aspects of the company's innovative solution which are crucial for the precise and stable implantation of its annuloplasty ring.

The U.S. patent (US1,223,931) protects our innovative locking method, which enables a secure and durable attachment of the annuloplasty ring to the mitral annulus. The method employs a unique self-locking mechanism that is activated after ring placement, providing enhanced stability and confidence in the long-term effectiveness of the procedure.

The Israeli patent (IL284329) also protects our innovative anchor design which features, radially expanding stabilizing loops, designed to provide a secure, multi-point fixation by expanding against the heart tissue upon deployment."

The EU patent (EP3448317) protects the core apparatus of our transcatheter heart valve repair system. This includes an innovative delivery system that houses multiple tissue anchors within an expandable annular structure.

"The issuance of these three new patents is an important milestone for VALFIX Medical and a testament to our team's unwavering commitment to innovation," said Mr. Eli Bar, CEO of VALFIX Medical. "The anchor and lock technologies are vital to the clinical success of our transcatheter approach, providing the enhanced stability and long-term durability necessary for a safe and effective treatment. This expanded IP portfolio solidifies our strategic position in the market and reinforces the confidence of our investors and partners as we advance toward clinical trials."

The VALFIX system, which utilizes a proprietary robotic interface, is designed to be delivered using a transseptal approach to the mitral annulus. Following the precise deployment of the company's patented sutures and anchors, the VALFIX ring is delivered onto the annulus to reduce its size and eliminate the regurgitation. The ring is then secured using the patented locks. This process offers a significant advantage over traditional open-heart surgery, providing a less invasive option for patients with Functional Mitral Regurgitation (FMR).

About VALFIX Medical Inc. VALFIX Medical is a privately held medical device company developing a groundbreaking robotic transcatheter Mitral valve repair system for the treatment of Functional Mitral Regurgitation (FMR). The company's innovative and game-changing robotic interface system is designed to provide cardiologists and surgeons with a precise and less invasive solution to alleviate heart failure symptoms, improve quality of life, and save lives.

To learn more about VALFIX Medical visit our website at www.valfixmed.com or contact us directly at info@valfixmed.com